Eli Lilly & Co. is becoming a leader in a new type of diabetes and weight loss treatment that Wall Street says could produce some of the biggest blockbusters of all time.

The Indianapolis, Indiana-based drugmaker said early Thursday that the diabetes drug Mounjaro brought in more than $500 million in revenue in the first quarter, exceeding sales in its first six months on the market.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.